## Contents

| Contributors list                          | vii |
| Editor biography                          | ix  |

### 1 Introduction and disease overview  
References  

#### 2 Incretin hormones as a target for therapy  
Incretin hormone physiology  
The incretin-producing cell  
GIP and GLP-1 action  
Measurement of the incretin hormones  
Incretin action in healthy individuals  
Incretin action in patients with type 2 diabetes  
Therapeutics application  
References  

#### 3 Glucagon-like peptide receptor agonists  
Introduction  
GLP-1 receptor agonists  
Extrapancreatic effects GLP-1 receptor agonists  
Pancreatic safety  
Perspectives  
References  

#### 4 Dipeptidyl peptidase-4 inhibitors  
Introduction  
Pharmacokinetics and pharmacodynamics  
Efficacy  
Combination therapy  
Use in specific patient populations  
Safety  

5 Global position and recommendations for use  61
   Introduction  61
   American Association of Clinical Endocrinologists/American College of Endocrinology  61
   American Diabetes Association /European Association for the Study of Diabetes  65
   International Diabetes Federation  65
   National Institute of Health and Care Excellence  67
   Using incretin-based therapies in clinical practice  70
   Availability and licences  71
   References  74

6 Future and emerging therapies  77
   Introduction  77
   Once-weekly agents under investigation  77
   Subcutaneous implants  81
   Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors  84
   Other indications for incretin therapies  85
   DPP-4 inhibitors  86
   References  89
Handbook of Incretin-based Therapies in Type 2 Diabetes
Gough, S. (Ed.)
2016, IX, 92 p. 20 illus., 16 illus. in color., Softcover
ISBN: 978-3-319-08981-2